Table 1.

Summary of reported case records and retrospective/prospective studies

References	Main organ involvement	Dose	Outcome
Gottenberg et al. [17]	Lymph nodes	4 × 375 mg/m2	Good
Belkhou et al. [15]	Lymph nodes	2 × 1 g, every 2 weeks	Good
Dasilva et al. [13]	Lymph nodes, including peritoneal	Two infusions, dose not specified	Good
Bomprezzi et al. [11]	CNS and skin	2 × 1 g, every 2 weeks, then 1 g every 6 months for 2 years	Good
Lower et al. [14]	Eye; 2 of 4 patients also had significant lung involvement	2 × 1 g, every 2 weeks, then 375 mg/m2 every 4 or 8 weeks for a minimum of 24 months or 1 g every 4 weeks for 10 months	Three responders of four patients
Sawaya et al. [12]	Neuromyelitis optica and lymph nodes	Single 1 g infusion	Good
Sweiss et al. [16]	Lung	2 × 1 g, every 2 weeks	Seven full or partial responders of ten patients